Adriana Meade, Marilina Santero, Olga Savall-Esteve, Javier Bracchiglione, Leire Leache, Anna Selva, Ismael Macias, Paula Cerdà, Xavier Bonfill Cosp
{"title":"Immunotherapy or Targeted Therapy Versus Best Supportive Care for Advanced Gastric Cancer: A Systematic Review and Meta-analysis of Randomized Trials.","authors":"Adriana Meade, Marilina Santero, Olga Savall-Esteve, Javier Bracchiglione, Leire Leache, Anna Selva, Ismael Macias, Paula Cerdà, Xavier Bonfill Cosp","doi":"10.1007/s12029-024-01155-y","DOIUrl":"10.1007/s12029-024-01155-y","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of non-chemotherapy anticancer drugs (immunotherapy or targeted therapy) compared to best supportive care (BSC) or placebo for the treatment of advanced gastric cancer (GC).</p><p><strong>Methods: </strong>Systematic review of randomized controlled trials (RCTs) searching (May 2022) MEDLINE, EMBASE, CENTRAL, Epistemonikos, ClinicalTrials.gov, and PROSPERO. Certainty of evidence was evaluated following GRADE.</p><p><strong>Results: </strong>Six RCTs included. Targeted therapies likely result in a slight increase in overall survival (OS) (HR 0.84, 95% CI 0.75, 0.93; moderate certainty) and progression-free survival (PFS) (HR 0.52, 95% CI 0.43, 0.62; moderate certainty). Toxicity had a slightly increased risk (RR 1.19, 95% CI 0.95, 1.48; low certainty). Immunotherapy also showed a likely improvement in PFS (HR 0.60, 95% CI 0.49, 0.73; moderate certainty), while toxicity showed a likely higher risk (RR 2.72, 95% CI 1.24, 5.94; moderate certainty). However, benefits in survival translated to time gains of slightly over a month for OS and less than a month for PFS. No data were reported on performance status (PS), hospital admissions, or quality of life (QoL).</p><p><strong>Conclusions: </strong>Our study suggests some survival benefits with low toxicity from these treatments, but gains are marginal. Uncertainties persist regarding their impact on QoL and outcomes for patients with poor PS. Caution is advised in treatment selection for advanced GC patients, who should actively participate in decision-making. Future research should include diverse patient populations and assess patient-centered outcomes with consistent comparator groups for BSC.</p><p><strong>Trial registration: </strong>The study protocol was registered in OSF ( https://doi.org/10.17605/OSF.IO/7CHX6 ) on 2022-04-01.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"75"},"PeriodicalIF":1.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Appropriateness of Recommendations for Surveillance Colonoscopy After Polypectomy-A Comparison of Adherence to the 2012 and 2020 USMSTF Guidelines.","authors":"Kacey Idouchi, Mathew J Gregoski, Don C Rockey","doi":"10.1007/s12029-025-01191-2","DOIUrl":"10.1007/s12029-025-01191-2","url":null,"abstract":"<p><strong>Purpose: </strong>The U.S. Multi-Society Task Force (USMSTF) has recommended surveillance intervals that weigh the benefits, harms, and costs of colonoscopy. In 2020, it updated its screening recommendations, and we want to evaluate clinical practice adherence to recommended guideline intervals.</p><p><strong>Methods: </strong>A prospective analysis was performed to examine gastroenterologists' recommendations for screening and surveillance colonoscopy from March 2012 to December 2023. Procedures with unknown histology or unsatisfactory bowel preparation were excluded. We compared polyp morphology, histology, and subsequent recommendations made by gastroenterologists to the USMSTF guidelines.</p><p><strong>Results: </strong>Five hundred thirteen patients and 902 colonoscopies were included. For screening colonoscopies, 200/231 (87%) followed 2012 guidelines, while 75% followed 2020 guidelines. For 1st surveillances, 75% followed 2012 guidelines, and 50% followed 2020 guidelines (p < 0.001). Adherence was also analyzed by year from 2020 to 2023. There were no significant differences in rates for screening colonoscopy and 1st surveillances over this time frame. Since the introduction of the 2020 guidelines for screening colonoscopies, there was a decrease in adherence by 13% for low-risk adenoma (LRA) and an 8% decrease for high-risk adenoma (HRA); there was a 7% increase in adherence for hyperplastic polyps (HP) and an 11% increase in adherence with sessile serrated polyps (SSP). For 1st surveillances, there was a decrease in adherence by 16% for LRA, 11% for HRA, 1% for HP, and 2% for SSP.</p><p><strong>Conclusions: </strong>Since the introduction of the 2020 guidelines, gastroenterologists are recommending colonoscopies more frequently than the guidelines call for. Increasing the evidence behind interval recommendations may increase guideline adherence.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"74"},"PeriodicalIF":1.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sedighe Hosseini Shabanan, Parnian Shobeiri, Amir Hossein Behnoush, Maryam Haghshomar, Kathryn J Fowler, Robert J Lewandowski
{"title":"<sup>90</sup>Y-Transarterial Radioembolization Combined with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review.","authors":"Sedighe Hosseini Shabanan, Parnian Shobeiri, Amir Hossein Behnoush, Maryam Haghshomar, Kathryn J Fowler, Robert J Lewandowski","doi":"10.1007/s12029-025-01189-w","DOIUrl":"https://doi.org/10.1007/s12029-025-01189-w","url":null,"abstract":"<p><strong>Background: </strong>Transarterial radioembolization with yttrium-90 (<sup>90</sup>Yt-TARE) and immune checkpoint inhibitors (ICIs) are emerging as treatment modalities for intermediate to advanced hepatocellular carcinoma (HCC) based on randomized controlled trials. Herein, we systematically reviewed the published literature on the effects of <sup>90</sup>Yt-TARE and ICIs combined on clinical outcomes of HCC.</p><p><strong>Methods: </strong>Medical databases of PubMed, Embase, and Cochrane Library were systematically searched for all studies assessing the use of concomitant immunotherapy of ICI with TARE in patients with HCC. Patient characteristics, treatment protocols, treatment outcomes, treatment adverse events, and survival outcomes were extracted after the screening phase. The primary outcomes were overall survival (OS) and patient-free survival (PFS), while the secondary outcomes were imaging objective response (OR) and adverse events.</p><p><strong>Results: </strong>Among 3432 reviewed, ten studies were included in this systematic review, including four randomized controlled trials and six retrospective studies. These consisted of 413 patients with HCC, and seven studies included patients with Child-Pugh A or B7 scores. Most studies allowed advanced or intermediate HCC stages, but only two specified BCLC stages (B and C). Median tumor sizes ranged from 56 to 78.5 mm. Various agents with different administration schedules were used as ICIs for immunotherapy by different studies for the combination of <sup>90</sup>Yt-TARE with ICIs. Median OS ranged from 16.2 to 27 months between different studies while the PFS also ranged from 5.6 to 13.3 months. The OR rates according to imaging-based response assessments were reported between 31 and 89%, and the incidence rate of any grade toxicities was between 50 and 80%.</p><p><strong>Conclusion: </strong>Concomitant treatment with <sup>90</sup>Yt-TARE and ICIs has shown promising results in the treatment of patients with HCC. Further studies are required to reach a consensus on the optimal treatment protocol and the outcome of these treatments for patients with intermediate to advanced HCC.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"73"},"PeriodicalIF":1.6,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peixu Lin, Meichen Ji, Tiantian Sun, Huanhuan Sun, Haiqing Ma
{"title":"Racial Disparities and Trends in Outcomes of Patients with Gastrointestinal Stromal Tumors.","authors":"Peixu Lin, Meichen Ji, Tiantian Sun, Huanhuan Sun, Haiqing Ma","doi":"10.1007/s12029-025-01195-y","DOIUrl":"https://doi.org/10.1007/s12029-025-01195-y","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. However, there are limited studies on the latest survival trends and the impact of racial disparities on GIST patients' outcomes.</p><p><strong>Methods: </strong>We obtained 12,808 GIST patients between 2001 and 2020 from the Surveillance, Epidemiology, and End Results (SEER) database in 17 original sites. Analysis utilizing the Kaplan-Meier method explored survival disparities and Cox regression was employed to assess the impact of prognostic factors.</p><p><strong>Results: </strong>Our study revealed an increase in the GIST incidence per 100,000 people over the past two decades, along with a rise in relative survival rate (RSR). Age, gender, social groups, tumor site, size, stage, socioeconomic status, marital status, surgery, and systemic therapy are prognostic factors. Subgroup analysis indicated higher incidence and poorer survival trends among Non-Hispanic Blacks (NHB) (Incidence, 1.88 per 100,000 people; 120 Mo RSR, 61.6%, 2001 to 2020). Colonic GIST has the worst prognosis among different locations, while rectal and anal GIST has the best. Within these groups, Non-Hispanic White (NHW) with colonic GIST have the poorest prognosis (HR, 2.032; 95% CI, 1.476-2.798), whereas NHB with rectal and anal GIST have the best prognosis.</p><p><strong>Conclusion: </strong>The incidence and RSR of GIST both increased during 2001-2020. NHW with colonic GIST showed poorer survival, while NHB with rectal and anal GIST revealed better survival, highlighting the importance of targeted clinical management for GIST.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"72"},"PeriodicalIF":1.6,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Trends in the Global Incidence of Pancreatic Cancer and a Brief Review of its Histologic and Molecular Subtypes.","authors":"Premila Devi Leiphrakpam, Sanjib Chowdhury, Michelle Zhang, Varnica Bajaj, Mashaal Dhir, Chandrakanth Are","doi":"10.1007/s12029-025-01183-2","DOIUrl":"https://doi.org/10.1007/s12029-025-01183-2","url":null,"abstract":"<p><p>The global burden of pancreatic cancer has more than doubled in recent decades. It is now the sixth leading cause of cancer-related death worldwide, with an estimated 510,922 new cases and 467,409 deaths in 2022. The incidence of the disease continues to rise annually, with projections indicating a 95.4% increase in new cases by 2050, potentially reaching a total of 998,663 new cases globally. The overall five-year survival rate for pancreatic cancer is 10% worldwide, showing only a modest improvement compared to the past decade. The rising trends in the incidence rates are likely to continue as the global population ages and access to healthcare improves. The relatively low survival rate is primarily attributed to late-stage diagnoses and the lack of an effective screening method. Currently, population-based screening for asymptomatic individuals is not recommended, highlighting the importance of identifying and monitoring individuals at high risk for pancreatic cancer. Numerous studies have highlighted the differences in the molecular pathology of pancreatic cancer, underscoring the need for continued research to better understand these differences. The silent progression of the disease, poor prognosis, lack of screening options, and the necessity to improve our comprehension of its molecular characteristics emphasize the critical need for ongoing monitoring of disease trends at the population level. This review article analyses trends in the incidence of pancreatic cancer and its histological subtypes and provides an update on its molecular subtypes.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"71"},"PeriodicalIF":1.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Changlin Gong, Maria Teresa Medina Rojas, Maria Gabriela Rubianes Guerrero, Michail Kladas, Arameh Mousakhanian, Aarushi Sudan, Adejoke Johnson, Kimberly Cartmill, Elana Sydney, Donald P Kotler
{"title":"Fecal Immunochemical Testing for Colorectal Cancer Prevention in Two Public Hospitals.","authors":"Changlin Gong, Maria Teresa Medina Rojas, Maria Gabriela Rubianes Guerrero, Michail Kladas, Arameh Mousakhanian, Aarushi Sudan, Adejoke Johnson, Kimberly Cartmill, Elana Sydney, Donald P Kotler","doi":"10.1007/s12029-025-01187-y","DOIUrl":"10.1007/s12029-025-01187-y","url":null,"abstract":"<p><strong>Introduction: </strong>The fecal immunochemical test (FIT) is highly effective in reducing colorectal cancer (CRC) mortality, but patient adherence to the screening process remains questionable. We present preliminary findings from a quality improvement (QI) initiative, in order to assess screening adherence and findings.</p><p><strong>Methods: </strong>All FIT specimens in a 30-month period were retrospectively examined. Patients with positive results were included, and information was collected via electronic medical record, including QI measures such as colonoscopy completion and findings. All data were de-identified. Patients were divided into \"asymptomatic group\" and \"symptomatic group\" based on clinical manifestations. Adherence and findings were analyzed.</p><p><strong>Results: </strong>FIT results were positive in 174 out of 2400 specimens. Colonoscopy was performed in 47.6% of all FIT-positive cases after a median interval of 5.5 (interquartile range, IQR 3-10) months, with 10% having CRC, 51.3% having adenomas, and 17.5% having advanced adenomas. Of all nine patients who had CRC, seven were in the symptomatic group. All five advanced cancers were found in the symptomatic group. Patients who actually completed colonoscopy were significantly younger than those who did not (median 61.5 years, IQR 56.5-69 years, vs. 64.5 years, IQR 59-71 years, P = 0.048). Patient-related reasons, primarily refusal, accounted for 65.9% of unperformed colonoscopies. No significant difference was found in adherence and yield between asymptomatic and symptomatic groups.</p><p><strong>Conclusion: </strong>Prevalence of colorectal adenomas and cancers is high in FIT-positive patients. A substantial number of CRCs and potentially preventable CRCs must have been missed because of low adherence rate, especially in older patients. Improving adherence to CRC screening in public hospitals requires enhanced patient engagement.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"69"},"PeriodicalIF":1.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Perioperative Radiation for Patients with Resectable Pancreatic Cancer: an Updated Review After the Initial RTOG 0848 Results.","authors":"Cymon N Kersch, Aaron J Grossberg","doi":"10.1007/s12029-025-01185-0","DOIUrl":"10.1007/s12029-025-01185-0","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic cancer remains one of the most lethal malignancies, with limited long-term survival despite advances in treatment strategies. While surgical resection offers the best chance for cure in localized disease, high rates of recurrence underscore the need for effective adjuvant therapies. Over four decades, the role of adjuvant chemoradiation (CRT) has been the subject of significant debate, with numerous trials yielding mixed outcomes regarding its impact on survival. Improvements in chemotherapy regimens and radiotherapy techniques have prompted renewed efforts to define the value of CRT, particularly in comparison to chemotherapy alone. The recent initial results of RTOG 0848 mark a critical milestone in this ongoing discussion, providing contemporary evidence that challenges established assumptions and refines patient selection criteria. By identifying specific subgroups-such as lymph node-negative patients-which may benefit from CRT, the trial offers clarity while highlighting the limitations of CRT in other populations.</p><p><strong>Methods: </strong>Herein, we review prior prospective and retrospective trials that investigated the role of perioperative CRT, in particular radiation therapy, for resectable pancreatic cancer.</p><p><strong>Results: </strong>This review examines the trajectory of research on CRT in pancreatic cancer, assesses the implications of RTOG 0848 for current clinical practice, and underscores the importance of further studies to optimize the integration of multimodal therapy in the management of this aggressive disease.</p><p><strong>Conclusion: </strong>The combination of results from RTOG 0848 in conjunction with the results of prior prospective and retrospective trials lend support for the use of adjuvant RT for patients with both lymph node-negative and lymph node-positive disease. However, several open questions remain about the role of this therapy in select patient cohorts, and whether neoadjuvant versus advent radiation is optimal.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"70"},"PeriodicalIF":1.6,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sandhya Kalavacherla, Nicholas Neel, Vasan Jagadeesh, Michael Bouvet, Andrew Lowy, Santiago Horgan, Winta T Mehtsun, Kaitlyn J Kelly
{"title":"Survival Outcomes Between Minimally Invasive and Open Gastrectomy in Early and Locally Advanced Gastric Adenocarcinoma in a Western Center.","authors":"Sandhya Kalavacherla, Nicholas Neel, Vasan Jagadeesh, Michael Bouvet, Andrew Lowy, Santiago Horgan, Winta T Mehtsun, Kaitlyn J Kelly","doi":"10.1007/s12029-024-01163-y","DOIUrl":"10.1007/s12029-024-01163-y","url":null,"abstract":"<p><strong>Purpose: </strong>While minimally invasive gastrectomy (MIS) is well-utilized in Asia, its adoption in the West to treat gastric adenocarcinoma has been slower. We compare survival outcomes between open gastrectomy and MIS in a high-volume Western US center.</p><p><strong>Methods: </strong>In this retrospective review, demographic and clinical characteristics of gastric adenocarcinoma patients who underwent curative-intent MIS (robotic or laparoscopic approaches) or open surgery were compared via descriptive statistics. Multivariable Cox hazard regression models were constructed to assess the effects of gastrectomy type on overall survival (OS) and recurrence-free survival (RFS) in the overall cohort and a locally advanced subgroup (pathologic stage 2-3 patients).</p><p><strong>Results: </strong>A total of 135 gastric adenocarcinoma patients were studied; 67% underwent MIS. Open patients experienced lower lymph node retrieval (p = 0.004) and neoadjuvant chemotherapy administration (p = 0.037) than MIS. OS (p = 0.18) and RFS (p = 0.74) were not different between MIS and open over a 5-year period. In multivariable survival models, gastrectomy type was not associated with OS (open hazard ratio (HR) = 1.78, p = 0.8 (compared to MIS)) or RFS (HR = 1.46, p = 0.7), while positive nodes (HR = 21.7, p = 0.003) and pathologic stage 3 (HR = 1.6, p = 0.025) were associated with poorer OS. Within the locally advanced cohort (N = 66, 67% MIS), OS (p = 0.43) and RFS (p = 0.72) were similarly not different between MIS and open patients.</p><p><strong>Conclusions: </strong>This study contributes to the growing body of evidence supporting the efficacy of MIS to manage gastric cancer within Western populations. Importantly, these data highlight the utility of MIS as a treatment option for locally advanced disease where uptake has been slowest.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"68"},"PeriodicalIF":1.6,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anush Sridharan, Efrat Dotan, Marianna Dorta, Navya Vemula, Elizabeth Handorf, Mengying Deng, Ashley Renning, Kristen Sorice, Lauren Laderman, Kate Whittington, Edna Cukierman, Igor Astsaturov, Namrata Vijayvergia, Joshua E Meyer, Sanjay S Reddy, Shannon M Lynch
{"title":"Racial/Ethnic Differences and Effects of Clinical/Socioeconomic Factors on Time from Diagnosis to Treatment in Pancreatic Cancer.","authors":"Anush Sridharan, Efrat Dotan, Marianna Dorta, Navya Vemula, Elizabeth Handorf, Mengying Deng, Ashley Renning, Kristen Sorice, Lauren Laderman, Kate Whittington, Edna Cukierman, Igor Astsaturov, Namrata Vijayvergia, Joshua E Meyer, Sanjay S Reddy, Shannon M Lynch","doi":"10.1007/s12029-025-01188-x","DOIUrl":"10.1007/s12029-025-01188-x","url":null,"abstract":"<p><strong>Purpose: </strong>Five-year survival for pancreatic adenocarcinoma (PDAC) is < 10% but can vary by a patient's race, socioeconomic status (SES), and the factors related to the neighborhood where a patient lives (nSES) . Prolonged time from diagnosis to first treatment (T2T) is another important disparity indicator. Here, we examined the effect of race, nSES, and patient-level clinical factors on T2T and survival in metastatic PDAC (mPDAC) patients.</p><p><strong>Methods: </strong>Patients with mPDAC treated at an academic cancer center between 2010 and 2018 (n = 334) were evaluated for nSES measures related to racial concentration, neighborhood deprivation, stability, immigration status, and transportation access from the US Census. We assessed and reported the effects of nSES and patient-level variables (age, race, gender, Charlson Comorbidity Index (CCI), etc.) on T2T and survival using univariate and multivariate Cox proportional hazards regression, hazard ratios (HR), confidence intervals (CI).</p><p><strong>Results: </strong>82.9% of the patients were White; 17.1% were Black. Median T2T was 26 days with no significant difference in T2T and survival by race. In multivariable models, no nSES variables were significantly associated with T2T. T2T did not significantly impact survival; however, receipt of chemotherapy (HR = 0.14 [95% CI = 0.06, 0.30]) was associated with better survival outcomes.</p><p><strong>Conclusion: </strong>Among patients with mPDAC, T2T was not associated with race/ethnic disparities or survival in a mostly White, high SES population treated at a comprehensive cancer center. Future investigations into pancreatic cancer disparities may be warranted in other hospital settings and in larger, more diverse study samples.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"67"},"PeriodicalIF":1.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Akram I Ahmad, Zaid Ansari, Tasneem Jamal Al-Din, Ritu Channagiri, Osama Sherjeel Khan, Fernando J Castro
{"title":"The Impact of Radiation Proctopathy on Secondary-Primary Colorectal Cancer in Patients with Prostate Cancer.","authors":"Akram I Ahmad, Zaid Ansari, Tasneem Jamal Al-Din, Ritu Channagiri, Osama Sherjeel Khan, Fernando J Castro","doi":"10.1007/s12029-025-01193-0","DOIUrl":"10.1007/s12029-025-01193-0","url":null,"abstract":"<p><strong>Purpose: </strong>We designed this study to evaluate the relationship between radiation proctopathy (RP) and the risk of colon and rectal cancer in prostate cancer patients.</p><p><strong>Methods: </strong>This is a retrospective cohort study evaluating patients with prostate cancer who received pelvic radiation therapy between January 2004 and January 2024. The study aims to compare the incidence of post-radiation rectal and colon cancer between patients who developed RP and patients who did not. We excluded patients with a previous history of colon cancer, colectomy, or inflammatory bowel disease.</p><p><strong>Results: </strong>In total, 12,629 met the inclusion criteria, 533 patients were diagnosed with RP, and 12,096 were without. We observed a higher incidence of colorectal cancer (3.75% vs. 0.63%), colon cancer (2.06% vs 0.40%), and rectal cancer (1.69% vs 0.23%) in patients with RP compared to those without PR (p < 0.001) during the follow-up period of 81 months for the RP group and 68 months for the non-RP group. PR was associated with colon and rectal cancer with an HR of 4.43 (95% CI, 2.29-8.57; p < 0.0001) and 7.27 (95% CI, 3.43-15.43; p < 0.0001), respectively.</p><p><strong>Conclusions: </strong>RP is an independent risk factor for developing rectal and colon cancer after pelvic radiation therapy in patients with prostate cancer.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"66"},"PeriodicalIF":1.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}